SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Allogene Therapeutics Inc. (ALLO) on Monday reported a loss of $65 million in its first quarter.
The South San Francisco, California-based company said it had a loss of 38 cents per share.
The results matched Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was also for a loss of 38 cents per share.
The immuno-oncology company posted revenue of $22,000 in the period, which also matched Street forecasts.
In the final minutes of trading on Monday, the company's shares hit $2.89. A year ago, they were trading at $6.18.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a ALLO">Zacks stock report on ALLO at https://www.zacks.com/ap/ALLO